Respiratory syncytial virus treatment market to exceed $2.3 billion by 2024
The global respiratory syncytial virus (RSV) treatment market is set to grow at the annual rate of 29.9%, over the next 10 years, driven by multiple new product launches in the currently sparse RSV arena, according to a report by GlobalData.
The research firm predicts the market will expand to over $2.3 billion by 2024 against $640 million in 2014. The market expansion will be witnessed across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, the UK, and Japan, the report said.
Christopher Pace, GlobalData’s director of infectious diseases, said that MedImmune's Synagis (palivizumab) is the only licensed product indicated for the prevention of RSV in infants at a high risk of severe infection, and there are no prophylactic agents approved for adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze